Lumican Antibody (1096907) [Alexa Fluor® 700]

• Reactivity: Hu
• Clone: 1096907
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 700

Lumican Antibody (1096907) [Alexa Fluor® 700] Summary

• Immunogen: Mouse myeloma cell line, NS0-derived human Lumican
  Gln19-Asn338
  Accession # P51884
• Specificity: Detects recombinant human Lumican protein in Direct ELISA.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Lumican Antibody (1096907) [Alexa Fluor® 700]

• KSPG lumican
• LDC
• LUM
• lumican proteoglycan
• Lumican
• SLRR2D
• SLRR2DLDCKeratan sulfate proteoglycan lumican

Background

Lumican is a 40 kDa member of the family of small leucine-rich repeat proteoglycans (SLRPs) and the class II subfamily (1). Human Lumican is synthesized as a 338 amino acid (aa) precursor that contains an 18 aa signal sequence and a 320 aa mature chain (SwissProt #: P51884). The mature chain contains a negatively charged N-terminal domain containing sulfated tyrosine and disulfide bonds, 12 leucine-rich repeats (LRRs), four potential sites of N-linked glycosylation, and a carboxyl terminal domain containing two conserved cysteines (1). Mature human Lumican is 88%, 87%, and 70% aa identical to mature mouse, rat, and chick Lumican, respectively. SLRPs constitute an important fraction of noncollagenous extracellular matrix proteins (ECM) proteins (1, 2). Lumican is expressed in a variety of tissues, including skin, artery, lung, cornea, kidney, bone, aorta, and articular cartilage (1). Lumican’s role in vivo has been found using Lumican null mice. These mice have functional deficits including corneal opacity as well as skin and tendon fragility associated with disorganized and loosely packed collagen fibers
(1, 3-6). The abnormal connective tissue phenotype seen in the Lumican null mice shows the importance of the role of Lumican in collagen fibrillogenesis (1). In addition to the control of collagen fibril assembly, Lumican has been shown to play a role in the regulation of cell proliferation (7, 8), migration (8, 9), and adhesion (9). Lumican’s over-expression has been reported in carcinoid tumor, breast, colorectal, neuroendocrine, uterine cervical and pancreatic cancers (10).

1. Nikitovic, D. et al. (2008) IUBMB Life 60:818.
2. Blochberger, T.C. et al. (1992) J. Biol. Chem. 267:347.
3. Chakravarti, S. et al. (1998) J. Cell Biol. 141:1277.
4. Chakravarti, S. et al. (2000) Invest. Ophthalmol. Vis. Sci. 41:3365.
5. Jepsen, K.J. et al. (2002) J. Biol. Chem. 277:35532.
6. Chakravarti, S. et al. (2003) Invest. Ophthalmol. Vis. Sci. 44:2422.
7. Vuillermoz, B. et al. (2004) Exp. Cell Res. 296:294.
8. Nikitovic, D. et al. (2008) FEBS J. 275:350.
9. D’Onofrio, M.F. et al. (2008) Biochem. Biophys. Res. Commun. 365:266.
10. Ishiwata, T. et al. (2007) Oncol. Rep. 18:537.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P51884()